Ovarian cancer
Conditions
Interventions
none:combined Capecitabine
Sponsors
The Second People's Hospital of Hefei
Eligibility
Sex/Gender
Female
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Aged =18 years old, female; 2. The pathological/cytology diagnosis of Advanced ovarian cancer 3. Have at least one measurable lesion (RECIST 1.1); 4. patients who have previously received =first line of standard chemotherapy and have a failure on the that treatment; "Treatment failure" definition: (1)disease progression during treatment or 6 months after the last treatment ,imaging or clinical evidence clearly show disease progressing; (2) patients giving up the standard Treatment,according to CTCAE 4.0 criterion,due to inability to tolerate adverse events, the intolerance of serious hematological adverse events upto grade IV degree (platelet reduction of more than III degree) or non-hematological adverse event more than III degree, and the researchers judge the subjects were still unable to tolerate the original regimen. 5. ECOG PS 0-2 points; 6. Expected survival = 3 months; 7. The main organ function, that meet the following criteria: (1) HB>=90 g/L; ANC>=1.5*10^9/L; PLT>=80*10^9/L; (2) TBIL 45 ml/min (Cockcroft-Gault formula); 8. women of childbearing age must have taken reliable contraceptive measures or 7 days before the group performed a pregnancy test (serum or urine), and the result is negative, and willing to experiment and during the last eight weeks after administration of the test drugs using appropriate methods contraception; 9. The subjects voluntarily joined the study, and informed consent; 10. According to the program requirements ,Patients are expected to take follow-up about their efficacy and adverse reactions.
Exclusion criteria
Exclusion criteria: 1. pregnant or lactating; 2. After suffering from high blood pressure and antihypertensive medications can not fall within the normal range (systolic blood pressure> 140 mmHg, diastolic blood pressure> 90 mmHg) above the level of suffering I myocardial ischemia,myocardial infarction, arrhythmia or Class II cardiac sufficiency; 3. coagulation abnormalities (INR> 1.5 or APTT>1.5ULN + 4 seconds, or APTT>1.5 ULN), having bleeding tendency,or treated with thrombolysis and anticoagulation; 4. Patients with clear gastrointestinal bleeding concerns(including the following situations: local active ulcerative lesions, and defecate occult blood (++)); A period of 6 months prior to the start of the study gastrointestinal bleeding event has occurred; 5. Accompanied by the central nervous system transfer; 6. Investigator judgment that may affect the conduct of clinical studies and case studies determined.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| DCR;ORR; | — |
Countries
China
Contacts
Public ContactBi Jinling
The Second People's Hospital of Hefei
Outcome results
None listed